Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | PF-06755992 |
Trade Name | |
Synonyms | PF 06755992|PF06755992 |
Drug Descriptions |
PF-06755992 is a cancer vaccine consisting of a AdC68 adenovirus engineered to express prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), and prostate stem cell antigen (PSCA), which may result in the induction of cytotoxic T-lymphocyte (CTL) response against PSA, PSMA, PSCA-expressing tumor cells and tumor cell killing (NCI Thesaurus). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C181900 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
PF-06755990 + PF-06755992 + Sunitinib + Tremelimumab | PF-06755990 PF-06755992 Sunitinib Tremelimumab | 0 | 1 |
PF-06755992 | PF-06755992 | 0 | 0 |